Iovance Biotherapeutics Inc (IOVA)vsVertex Pharmaceuticals Inc (VRTX)
IOVA
Iovance Biotherapeutics Inc
$3.79
-7.56%
HEALTHCARE · Cap: $1.84B
VRTX
Vertex Pharmaceuticals Inc
$446.83
-0.03%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 4178% more annual revenue ($12.22B vs $285.61M). VRTX leads profitability with a 35.5% profit margin vs -123.9%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
IOVA
Avoid34
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IOVA.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 44.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -47.5% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IOVA
The strongest argument for IOVA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 44.8% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : IOVA
The primary concerns for IOVA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IOVA profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
IOVA carries more volatility with a beta of 0.70 — expect wider price swings.
IOVA is growing revenue faster at 44.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 34/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iovance Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?